Lovastatin decreases de novo cholesterol synthesis and LDL apo B-100 production rates in combined-hyperlipidemic males

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 10, 1997, Pages 1910-1917

  Cuchel, Marina ^a   Schaefer, Ernst J ^a   Millar, John S ^a   Jones, Peter J H ^b   Dolnikowski, Gregory G ^a   Vergani, Carlo ^c   Lichtenstein, Alice H ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Apo B 100; Cholesterol; Fractional catabolic rate; Hyperlipidemia; Kinetics; Lipoproteins; Lovastatin; Production rate

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; HYPOLIPEMIA; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031469633     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.10.1910     Document Type: Article

References (16)

1. The Expert Panel. Summary of the second report of the National Cholesterol Education Program Expert Panel on detection, evaluation, treatment of high blood cholesterol in adults. JAMA. 1993;269:3015-3023.
2. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
3. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
4. Frick MH, Elo O, Haapa K, Heininen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
6. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
7. Illingworth DR, Sexton GT. Hypocholesterolemic effects of mevilonin in patients with heterozygous familial hypercholesterolemia. J Clin Invest. 1984;74:1972-1978.
8. Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, Bacon SR, Bolognese JA, Frost PH, Lamkin GE, Lees AM, Leon AS, Gardner K, Johnson G, Mellies MJ, Rhymer PA, . Tun P. Lovastatin (mevilonin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Ann Intern Med. 1987;107:609-615.
9. The Lovastatin Study Group. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: a multicentric study. JAMA. 1986;256:2829-2834.
10. Grundy SM, Vega GL. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res. 1985;26:1464-1475.
11. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res. 1990;31:567-582.
12. Illingworth DR, O'Malley JP. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipidemia. Metabolism. 1990;39:403-409.
13. Vega GL, East C, Grundy SM. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis. 1988;70:131-143.
14. Grundy SM, Bilheimer DW. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci USA. 1984;81:2538-2542.
15. Pappu AS, Ilingworth DR. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. J Lab Clin Med. 1989;114:554-562.
16. Pappu AS, Illingworth DR, Bacon S. Reduction in plasma low density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Metabolism. 1989;38:542-549.